

Dear Clients and Partners,

This message follows our seven previous weekly memos, which you can all consult here:

<https://symbioticsgroup.com/covid-19/>

The key overview elements of this eight week into the pandemic for us are the following:

- **Technical assistance support:** The effect on the Covid 19 crisis on some MFIs are quite strong. To help them cope with this exceptional situation, Symbiotics has developed a comprehensive Technical Assistance package that provides assistance during and post-crisis to affected investee MFIs. The program tackles operations continuity, HR, finance, IT/disaster recovery, governance and risk management. Furthermore, this 1<sup>st</sup> edition focuses on digital channels to ensure operational continuity via the continued provision of financial services, and on raising the MFI clients' (consumers, SMEs, etc.) awareness on health, safety and best business practices, increasing their financial literacy and their capability on the use of the technology-driven solutions and products. Part of the program is already in implementation, particularly in Africa, and we are in discussion with several DFIs and foundation to enlarge its scope.
- **Liquidity cases:** We have started implementing the MoU signed 2 weeks ago with 8 other leading MIVs. Thanks to this coordination with our peers, out of the 50 MFIs that were previously in liquidity stress, agreements are already established for 27 MFIs. Those MFIs are not anymore facing an immediate liquidity risk. Over the past week, 6 new MFIs expressed some liquidity stress situation, leaving the open cases to a total of 39.
- **Solvency cases:** No new "solvency cases" have been identified, keeping the number to 3 (or 1.0% of investee headcount, representing 0.3% of overall volumes).
- **Fundraising:** We expect new subscriptions for around 120m\$ to come by end May for some closed end-funds, while 2 of the open-ended funds we advise or manage received some redemptions requests in the last week for a level of around 40m\$ due by September 2020. As a reminder, Symbiotics has a total of 2.3b\$ assets under management.
- **Pipeline/New investments:** After a wait-and-see strategy in April, characterized by a relatively low level of disbursements, amounting to 30m\$, we are processing 30m\$ of transactions for the coming 2 weeks, materializing the gradual deployment of the 400m\$ opportunities identified for the coming 3 months.
- **Sector coordination:** Discussion are going on with several DFIs and a couple of large mainstream private institutional investors to use Symbiotics' existing bond platform to syndicate part of the pipeline mentioned above in a blended finance and private public partnership approach. We are also in discussion with CGAP and other industry associations to continue steering our joint collaboration amongst the many MIVs and impact funds refinancing our industry.

Please liaise directly with your relationship manager for portfolio specific situations and perspectives.

Yours sincerely,  
Symbiotics